Teladoc (NYSE:TDOC) shares reached a new 52-week high and low on Thursday . The company traded as low as $50.70 and last traded at $50.60, with a volume of 673212 shares trading hands. The stock had previously closed at $49.85.
A number of analysts recently commented on the stock. Craig Hallum set a $39.00 price target on shares of Teladoc and gave the company a “hold” rating in a research note on Wednesday, May 2nd. Cantor Fitzgerald restated a “hold” rating and set a $35.00 price target (up from $31.00) on shares of Teladoc in a research note on Tuesday, February 27th. Chardan Capital restated a “buy” rating and set a $47.00 price target (down from $48.00) on shares of Teladoc in a research note on Wednesday, February 28th. SunTrust Banks upped their price target on shares of Teladoc to $48.00 and gave the company a “positive” rating in a research note on Wednesday, May 2nd. Finally, ValuEngine upgraded shares of Teladoc from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Teladoc currently has a consensus rating of “Buy” and an average price target of $42.67.
The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.15 and a current ratio of 4.15. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -30.67 and a beta of 0.35.
Teladoc (NYSE:TDOC) last posted its earnings results on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.04. The business had revenue of $89.64 million for the quarter, compared to analyst estimates of $86.77 million. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. Teladoc’s revenue was up 109.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.30) EPS. equities analysts predict that Teladoc will post -1.37 earnings per share for the current year.
In other news, CEO Jason N. Gorevic sold 25,000 shares of the stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $48.93, for a total value of $1,223,250.00. Following the transaction, the chief executive officer now owns 636,184 shares of the company’s stock, valued at approximately $31,128,483.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Mark Hirschhorn sold 69,460 shares of the stock in a transaction on Wednesday, May 2nd. The stock was sold at an average price of $43.73, for a total transaction of $3,037,485.80. Following the completion of the transaction, the vice president now directly owns 50,042 shares in the company, valued at approximately $2,188,336.66. The disclosure for this sale can be found here. Insiders have sold a total of 483,954 shares of company stock worth $19,960,682 in the last ninety days. 3.95% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of TDOC. Carillon Tower Advisers Inc. bought a new position in shares of Teladoc in the 4th quarter worth $57,973,000. Global Thematic Partners LLC bought a new position in shares of Teladoc in the 1st quarter worth $51,465,000. Champlain Investment Partners LLC bought a new position in shares of Teladoc in the 4th quarter worth $29,290,000. Alliancebernstein L.P. increased its holdings in shares of Teladoc by 15.7% in the 4th quarter. Alliancebernstein L.P. now owns 4,472,612 shares of the health services provider’s stock worth $155,871,000 after buying an additional 607,002 shares during the last quarter. Finally, Bamco Inc. NY increased its holdings in shares of Teladoc by 32.7% in the 4th quarter. Bamco Inc. NY now owns 1,931,500 shares of the health services provider’s stock worth $67,313,000 after buying an additional 475,600 shares during the last quarter.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.